{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:57:54Z","timestamp":1761512274686},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T00:00:00Z","timestamp":1153958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00228-006-0144-9","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T08:35:24Z","timestamp":1153902924000},"page":"737-742","source":"Crossref","is-referenced-by-count":8,"title":["Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring"],"prefix":"10.1007","volume":"62","author":[{"given":"A. M.","family":"Almeida","sequence":"first","affiliation":[]},{"given":"A. C.","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"F.","family":"Sales","sequence":"additional","affiliation":[]},{"given":"I.","family":"Baldeiras","sequence":"additional","affiliation":[]},{"given":"M. J.","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"M. M.","family":"Caramona","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2006,7,27]]},"reference":[{"key":"144_CR1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","volume":"345","author":"MJ Brodie","year":"1995","unstructured":"Brodie MJ, Richens A, Yuen AWC (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476\u2013479","journal-title":"Lancet"},{"key":"144_CR2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1528-1157.1999.tb05562.x","volume":"40","author":"TJ Steiner","year":"1999","unstructured":"Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R (1999) Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40:601\u2013607","journal-title":"Epilepsia"},{"key":"144_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-1211(99)00039-X","volume":"37","author":"MJ Brodie","year":"1999","unstructured":"Brodie MJ, Overstall PW, Giorgi L, The UK Lamotrigine Elderly Study Group (1999) Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 37:81\u201387","journal-title":"Epilepsy Res"},{"key":"144_CR4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1345\/aph.1A102","volume":"36","author":"SC Hurley","year":"2002","unstructured":"Hurley SC (2002) Lamotrigine update and its use in mood disorders. Ann Pharmacother 36:860\u2013873","journal-title":"Ann Pharmacother"},{"key":"144_CR5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"AF Cohen","year":"1987","unstructured":"Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal man. Clin Pharmacol Ther 42:535\u2013541","journal-title":"Clin Pharmacol Ther"},{"key":"144_CR6","first-page":"1166","volume":"260","author":"J Magdalou","year":"1992","unstructured":"Magdalou J, Herber R, Bidault R, Siest G (1992) In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 260:1166\u20131173","journal-title":"J Pharmacol Exp Ther"},{"key":"144_CR7","first-page":"299","volume":"23","author":"MD Green","year":"1995","unstructured":"Green MD, Bishop WP, Tephy TR (1995) Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23:299\u2013302","journal-title":"Drug Metab Dispos"},{"key":"144_CR8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0920-1211(87)90041-6","volume":"1","author":"S Jawad","year":"1987","unstructured":"Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A (1987) Lamotrigine: single-dose pharmacokinetics and initial 1\u00a0week experience in refractory epilepsy. Epilepsy Res 1:194\u2013201","journal-title":"Epilepsy Res"},{"key":"144_CR9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","volume":"33","author":"AWC Yuen","year":"1992","unstructured":"Yuen AWC, Land G, Weatherley BC, Peck AW (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33:511\u2013513","journal-title":"Br J Clin Pharmacol"},{"key":"144_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","volume":"60","author":"GD Anderson","year":"1996","unstructured":"Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 60:145\u2013156","journal-title":"Clin Pharmacol Ther"},{"key":"144_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00007691-199904000-00006","volume":"21","author":"Y Bottiger","year":"1999","unstructured":"Bottiger Y, Svensson J, Stahle L (1999) Lamotrigine drug interactions in a TDM material. Ther Drug Monit 21:171\u2013174","journal-title":"Ther Drug Monit"},{"key":"144_CR12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s002280050001","volume":"55","author":"T Tomson","year":"2000","unstructured":"Tomson T, Johannessen SI (2000) Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 55:697\u2013705","journal-title":"Eur J Clin Pharmacol"},{"key":"144_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry Dj, Bialer M, Kr\u00e4mer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347\u2013363","journal-title":"Ther Drug Monit"},{"key":"144_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-4347(01)00044-5","volume":"755","author":"MM Castel-Branco","year":"2001","unstructured":"Castel-Branco MM, Almeida AM, Falc\u00e3o AC, Macedo TA, Caramona MM, Lopez FG (2001) Lamorigine analysis in blood and brain by high-performance liquid chromatography. J Chromatogr B 755:119\u2013127","journal-title":"J Chromatogr B"},{"key":"144_CR15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biop 9:503\u2013513","journal-title":"J Pharmacokinet Biop"},{"key":"144_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","volume":"18","author":"TW May","year":"1996","unstructured":"May TW, Rambeck B, J\u00fcrgens U (1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18:523\u2013531","journal-title":"Ther Drug Monit"},{"key":"144_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007691-199712000-00003","volume":"19","author":"D Battino","year":"1997","unstructured":"Battino D, Croci D, Granata T, Estienne M, Pisani F, Avanzini G (1997) Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther Drug Monit 19:620\u2013627","journal-title":"Ther Drug Monit"},{"key":"144_CR18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","volume":"19","author":"A Bartoli","year":"1997","unstructured":"Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perucca E (1997) The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 19:252\u2013260","journal-title":"Ther Drug Monit"},{"key":"144_CR19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","volume":"21","author":"JA Armijo","year":"1999","unstructured":"Armijo JA, Bravo J, Cuadrado A, Herranz JL (1999) Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 21:182\u2013190","journal-title":"Ther Drug Monit"},{"key":"144_CR20","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","volume":"12","author":"WR Garnett","year":"1997","unstructured":"Garnett WR (1997) Lamotrigine: pharmacokinetics. J Child Neurol 12:S10\u2013S15","journal-title":"J Child Neurol"},{"key":"144_CR21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","volume":"39","author":"TH Grasela","year":"1999","unstructured":"Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39:373\u2013384","journal-title":"J Clin Pharmacol"},{"key":"144_CR22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","volume":"23","author":"V Chan","year":"2001","unstructured":"Chan V, Morris RG, Ilett KF, Tett SE (2001) Population Pharmacokinetics of lamotrigine. Ther Drug Monit 23:630\u2013635","journal-title":"Ther Drug Monit"},{"key":"144_CR23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1528-1157.2003.46902.x","volume":"44","author":"DV Lardizabal","year":"2003","unstructured":"Lardizabal DV, Morris Hh, Hovinga CA, Carre\u00f1o M (2003) Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring unit. Epilepsia 44:536\u2013539","journal-title":"Epilepsia"},{"key":"144_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","volume":"31","author":"R Riva","year":"1996","unstructured":"Riva R, Albani F, Contin M, Baruzzi A (1996) Pharmacokinetic interactions between antiepileptic drugs: Clinical considerations. Clin Pharmacokinet 31:470\u2013493","journal-title":"Clin Pharmacokinet"},{"key":"144_CR25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","volume":"47","author":"A Sabers","year":"2001","unstructured":"Sabers A, Buchholt JM, Uldall P, Hansen EL (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 47:151\u2013154","journal-title":"Epilepsy Res"},{"key":"144_CR26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007691-200012000-00003","volume":"22","author":"RG Morris","year":"2000","unstructured":"Morris RG, Black AB, Lam E, Westley IS (2000) Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 22:656\u2013660","journal-title":"Ther Drug Monit"},{"key":"144_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","volume":"57","author":"BE Gidal","year":"2003","unstructured":"Gidal BE, Sheth R, Parnell J, Maloney K, Sale M (2003) Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetic: implications for conversion to lamotrigine monotherapy. Epilepsy Res 57:85\u201393","journal-title":"Epilepsy Res"},{"key":"144_CR28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000066165","volume":"48","author":"P Benetello","year":"2002","unstructured":"Benetello P, Furlanut M, Baraldo M, Tonon A, Furlanut M (2002) Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. Eur Neurol 48:200\u2013203","journal-title":"Eur Neurol"},{"key":"144_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457\u2013465","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0144-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0144-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0144-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:30Z","timestamp":1558702290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0144-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0144-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,27]]}}}